Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a
biotechnology company developing next-generation cell and gene
therapies using its proprietary Gene Circuit platform, today
announced the publication of preclinical data demonstrating the
ability of natural killer (NK) cells engineered with multi-input
Gene Circuits to selectively target and eliminate leukemic cells,
including both blasts and leukemic stem cells, while sparing
healthy stem cells. The data was published in Cell Reports on April
25, 2024.
The publication, titled “Precision off-the-shelf natural killer
cell therapies for oncology with logic-gated gene circuits,”
demonstrates the activity of logic-gated NK cells in vitro and in
vivo preclinical studies.
“AML, an aggressive form of leukemia with a poor prognosis, has
long presented a challenge for targeted therapies due to the lack
of a single tumor-associated antigen that distinguishes cancer
cells from healthy cells,” said Timothy Lu, MD, PhD, Chief
Executive Officer and Co-Founder of Senti Bio. “By harnessing the
power of logic-gated NK cells, this preclinical data demonstrates
SENTI-202’s ability to precisely target and eliminate leukemic
cells while sparing healthy stem cells, thereby illustrating the
potential to minimize the risk of harmful side effects and
maximizing the potential for deep therapeutic efficacy. We are
encouraged about the possibility of translating these findings into
our Phase 1 clinical trial of SENTI-202, which is on track to begin
this quarter, offering new hope for patients with limited options
today."
The peer-reviewed publication describes preclinical studies of
engineered NK cells with a Gene Circuit consisting of chimeric
antigen receptors (CARs) controlled by OR and NOT logic gates. This
approach allows NK cells to detect and respond to multiple antigen
inputs, enabling precise targeting of AML cells while protecting
healthy cells. Using the OR gate, NK cells were able to kill a
range of AML cells, including leukemic stem cells and blasts, by
recognizing FLT3 and/or CD33, which are validated therapeutic
targets for AML. The NOT gate component of the Gene Circuit
protected healthy HSCs by reducing CAR-mediated killing through an
inhibitory CAR recognizing the endomucin antigen, which is
selectively expressed on healthy HSCs but not cancer cells. In
preclinical mouse models, the engineered NK cells killed multiple
AML subtypes while protecting primary hematopoietic stem cells
(HSCs).
This data supports the design of Phase 1 clinical trial of
SENTI-202, a potential first-in-class, off-the-shelf logic-gated
CAR-NK investigational cell therapy for the treatment of AML. Senti
Bio is on track to initiate patient dosing in the second quarter of
2024, with initial efficacy data anticipated by year-end 2024 and
initial durability data following in 2025.
About Senti BioSenti Biosciences is a
biotechnology company developing a new generation of cell and gene
therapies for patients living with incurable diseases. To achieve
this, Senti Bio is leveraging a synthetic biology platform called
Gene Circuits to create therapies with enhanced precision and
control. These Gene Circuits are designed to precisely kill cancer
cells, spare healthy cells, increase specificity to target cells
and control the expression of drugs even after administration. The
Company’s wholly-owned pipeline utilizes off-the-shelf chimeric
antigen receptor natural killer (CAR-NK) cells, outfitted with Gene
Circuits, to target challenging liquid and solid tumor indications.
Senti Bio has also preclinically demonstrated the potential breadth
Gene Circuits in other modalities, diseases outside of oncology,
and continues to advance these capabilities through partnerships
with Spark Therapeutics and BlueRock Therapeutics.
Forward-Looking StatementsThis press release
and document contain certain statements that are not historical
facts and are considered forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements generally are identified by the
words “believe,” “could,” “predict,” “continue,” “ongoing,”
“project,” “expect,” “anticipate,” “estimate,” “intend,”
“strategy,” “future,” “opportunity,” “plan,” “may,” “should,”
“will,” “would,” “will be,” “will continue,” “will likely result,”
“forecast,” “seek,” “target” and similar expressions that predict
or indicate future events or trends or that are not statements of
historical matters. Forward-looking statements are predictions,
projections, and other statements about future events that are
based on current expectations of Senti Bio’s management and
assumptions, whether or not identified in this document, and, as a
result, are subject to risks and uncertainties. Forward-looking
statements include, but are not limited to; expectations regarding
its growth, strategy, progress and timing of its preclinical
studies, including SENTI-202, and clinical trials, including the
anticipated dosing of patients and availability of data, and the
timing thereof; the ability of any product candidate to perform in
humans in a manner consistent with earlier nonclinical, preclinical
or clinical trial data; and the ability to initiate new clinical
programs. These forward-looking statements are provided for
illustrative purposes only and are not intended to serve as and
must not be relied on by any investor as, a guarantee, an
assurance, a prediction, or a definitive statement of fact or
probability. Actual events and circumstances are difficult or
impossible to predict and will differ from assumptions. Many actual
events and circumstances are beyond the control of Senti Bio. Many
factors could cause actual future results to differ materially from
the forward-looking statements in this document, including but not
limited to: (i) changes in domestic and foreign business, market,
financial, political and legal conditions, (ii) changes in the
competitive and highly regulated industries in which Senti Bio
operates, variations in operating performance across competitors,
changes in laws and regulations affecting Senti Bio’s business,
(iii) the ability to implement business plans, forecasts and other
expectations, (iv) the risk of downturns and a changing regulatory
landscape in Senti Bio’s highly competitive industry, (v) risks
relating to the uncertainty of any projected financial information
with respect to Senti Bio, (vi) risks related to uncertainty in the
timing or results of Senti Bio’s clinical trial start up, clinical
studies, patient enrollment, and GMP manufacturing startup
activities, (vii) Senti Bio’s dependence on third parties in
connection with clinical trial startup, clinical studies, and GMP
manufacturing activities, (viii) risks related to delays and other
impacts from macroeconomic and geopolitical events, increasing
rates of inflation and rising interest rates on business
operations, and (ix) the success of any future research and
development efforts by Senti Bio. The foregoing list of factors is
not exhaustive. You should carefully consider the foregoing factors
and the other risks and uncertainties described in the “Risk
Factors” section of Senti Bio’s Annual Report on Form 10-K, filed
with the SEC on March 21, 2024, and other documents filed by Senti
Bio from time to time with the SEC, and other documents filed by
Senti Bio from time to time with the SEC. These filings identify
and address other important risks and uncertainties that could
cause actual events and results to differ materially from those
contained in the forward-looking statements in this document. There
may be additional risks that Senti Bio does not presently know, or
that Senti Bio currently believes are immaterial that could also
cause actual results to differ from those contained in the
forward-looking statements in this document. Forward-looking
statements speak only as of the date they are made. Senti Bio
anticipates that subsequent events and developments may cause Senti
Bio’s assessments to change. Except as required by law, Senti Bio
assumes no obligation to update publicly any forward-looking
statements, whether as a result of new information, future events,
or otherwise.
Availability of Other Information About Senti
Biosciences, Inc.For more information, please visit the
Senti Bio website at https://www.sentibio.com or follow Senti Bio
on Twitter (@SentiBio) and LinkedIn (Senti Biosciences). Investors
and others should note that we communicate with our investors and
the public using our company website (www.sentibio.com), including,
but not limited to, company disclosures, investor presentations and
FAQs, Securities and Exchange Commission filings, press releases,
public conference call transcripts and webcast transcripts, as well
as on Twitter and LinkedIn. The information that we post on our
website or on Twitter or LinkedIn could be deemed to be material
information. As a result, we encourage investors, the media and
others interested to review the information that we post there on a
regular basis. The contents of our website or social media shall
not be deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended.
Senti Bio Contacts Investors:
investors@sentibio.com Media: media@sentibio.com
Senti Biosciences (NASDAQ:SNTI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Senti Biosciences (NASDAQ:SNTI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024